Galectin Therapeutics secures $10M line of credit from Chairman Uihlein; extends existing debt to Sept 2026

GALECTIN THERAPEUTICS INC

Richard E. Uihlein provides up to $10M unsecured line of credit; draws through April 2026, principal & interest due Sept 30, 2026.
Interest at Applicable Federal Rate (currently 4.05%) plus 2%; conversion price floor $3.00 per share.
Up to 200,000 warrants issued ratably; exercise price 150% of closing price, capped at $10, floor $3.
Company extends existing $81M in convertible notes & lines of credit to September 30, 2026.
Board approves $100K retention bonuses for CMO Dr. Khurram Jamil & CFO Jack Callicutt; partnership bonus if belapectin deal by Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.